Published: November 2025 | Last updated: May 2026
An injection every two months. That is the rhythm of HIV care that real-world evidence now backs for adults in their sixties, seventies, and beyond. Spain's RELATIVITY cohort tracked 370 people aged 60 and older on long-acting cabotegravir plus rilpivirine and reported high virologic suppression with low failure rates, even with the higher comorbidity load that comes with age (Troya et al., HIV Medicine, 2025). A separate January 2026 study followed 135 people over 65 on the same regimen and saw HIV RNA stay below 50 copies per milliliter in every participant through a median 17 months of follow-up (Open Forum Infectious Diseases, 2026).
Fewer pills, less mental load, more freedom for people who have managed HIV for decades. The shift is real. So is the responsibility to keep monitoring it. This guide walks through what changed in the evidence, where at-home rapid testing fits between injections, and how to think about timing when daily oral medication is no longer the anchor of your care routine.
Who this guide is for
If you are over 50 and living with HIV, or caring for someone who is, the healthcare system was not built around your experience. You might be balancing multiple medications, juggling specialist appointments, or carrying the weight of a diagnosis you have lived with for decades. For others, the question is newer. HIV diagnoses among adults over 50 are a meaningful share of new cases in the United States, and that group brings its own concerns about disclosure, mobility, and stigma.
This guide is written for older adults already living with HIV, people newly diagnosed at midlife or later, partners and caregivers, and anyone weighing whether long-acting injectable therapy fits their life. It covers how to time testing, what to expect from different test types, how at-home rapid kits work alongside clinic care, and what to do if a result during the gap between injections is reactive.
- Older adults already living with HIV who are weighing or already using long-acting injectable therapy.
- People newly diagnosed at midlife or later trying to understand what treatment options now look like.
- Partners and caregivers helping coordinate appointments, refills, and between-visit monitoring.
- Anyone considering the switch from daily oral antiretroviral therapy to a shot every two months.
What the new evidence actually shows
The headline study is the RELATIVITY cohort out of Spain, a real-world observational dataset across multiple healthcare institutions. The 60-and-over subgroup included 370 participants (median age 63), with longer prior antiretroviral exposure, more comorbidities, and lower historical CD4 nadirs than the under-60 comparison group. Adherence ran higher in the older group than in younger participants, and virologic suppression rates were comparable across age groups, with a low failure rate overall (Troya et al., HIV Medicine, October 2025; specific adherence percentages drawn from the RELATIVITY print edition).
A second analysis published in Open Forum Infectious Diseases in January 2026 zeroed in on the over-65 group: 135 people on bimonthly cabotegravir plus rilpivirine, median follow-up of 17.4 months, and HIV RNA below 50 copies per milliliter in all of them. The authors flagged an 11.1 percent discontinuation rate, mostly tied to tolerability issues (injection-site reactions, myalgia, or fever) and patient preference, with rare serious adverse events including one case of hepatitis B reactivation about 19 months into treatment. Their conclusion was direct: older age should not be a barrier to this treatment strategy (Open Forum Infectious Diseases, January 2026).
The studies are observational, not randomized trials, and absolute sample sizes for the oldest groups remain modest. Still, the picture is consistent across both datasets: the bimonthly injectable holds the line on viral suppression in older adults, including those with comorbidities and decades of treatment behind them.
RELATIVITY cohort (Spain, 2025): 370 participants aged 60 and older on bimonthly cabotegravir plus rilpivirine, with adherence reportedly higher in this group than in younger comparators and a low failure rate overall.
OFID 65+ study (January 2026): 135 participants on the same regimen, HIV RNA below 50 copies per milliliter in 100 percent of participants at a median 17.4-month follow-up. The 11.1 percent who discontinued did so largely because of tolerability (injection-site reactions, myalgia, or fever) or personal preference, with rare serious adverse events including one HBV reactivation.
Why testing still matters on a long-acting regimen
Switching from a daily pill to a shot every two months changes the geometry of your care. The visible reminder of HIV is no longer in your pill organizer; it is in your calendar, two months out. That can feel like relief. It can also let monitoring habits slip if no one builds new ones in their place.
Here is what matters between appointments. Long-acting cabotegravir plus rilpivirine is highly effective when administered on schedule, but the regimen depends on the schedule. Most rebound is rare, yet the risk window opens when doses slip. That is when an at-home rapid HIV test, used as a check-in rather than a diagnostic, earns its place.
For someone newly diagnosed in midlife, or anyone newly considering an injectable regimen, the same logic applies in reverse. A baseline picture of your status, plus regular check-ins, sets you up to catch a problem early instead of waiting to see what shows up at the next clinic visit. HIV.gov's treatment overview describes long-acting injectables as an option for people who meet specific clinical criteria, which means your provider will weigh things like prior resistance history, hepatitis B status, and adherence pattern before recommending the switch.
A missed or significantly delayed injection can let drug levels drift below the threshold needed to keep the virus suppressed. That is the window an at-home rapid HIV test is designed to catch. Used as a between-visit check-in, it flags a problem early so you can call your provider before the gap widens.
What counts as a test, and which one does what
Not every HIV test does the same thing. Diagnostic options fall into three main categories, and knowing the difference matters when you are choosing between a home kit and a clinic visit. The table below summarizes how they compare on detection window and where each fits best.
One key distinction. Rapid antibody tests, including the kits sold for at-home use, are the right tool for between-clinic screening. They are not a substitute for the viral load measurement your clinic runs on a lab NAT. If a rapid result is reactive in someone who has been suppressed for years, the next step is a clinic visit for a confirmatory NAT, not a conclusion about the regimen.
| Test Category | What It Detects | Earliest Detection Window | Best Use |
|---|---|---|---|
| Nucleic acid test (NAT or PCR) | HIV RNA in blood (the virus itself) | 10 to 33 days after exposure | Earliest infection detection; clinic viral load measurement on a long-acting regimen |
| Antigen + antibody combo (lab) | p24 antigen plus HIV antibodies | 18 to 45 days after exposure | Standard clinic screening at routine visits |
| Rapid antibody (at-home or point-of-care) | HIV antibodies only | Reliable around 90 days after exposure | Between-clinic check-ins, especially around a missed or delayed injection |
Window periods, and why timing matters
A window period is the gap between exposure to an infection and the point when a test can reliably detect it. Test too early, and a false negative is possible even when the infection is present. That is the most common reason a home test gives reassurance that turns out to be wrong, and it is the single biggest variable in choosing when to test after a possible exposure.
Window periods vary by infection and by the type of test. They also vary slightly with immune response, which can be modestly slower in older adults. The table below summarizes typical windows for common STIs and HIV across the test types you are most likely to encounter.
| Infection | Common Test Type | Sample | Typical Window Period | When Accuracy Peaks |
|---|---|---|---|---|
| HIV | Antibody / Ag-Ab combo / NAT | Blood or oral fluid | Antibody: 23 to 90 days. Ag-Ab combo: 18 to 45 days (lab). NAT: 10 to 33 days. | Around 90 days for antibody tests |
| Syphilis | Treponemal antibody | Blood (fingerstick or venous) | 3 to 6 weeks | 6 to 12 weeks |
| Chlamydia | NAAT | Urine or swab | 7 to 14 days | After 14 days |
| Gonorrhea | NAAT | Urine or swab | 7 to 14 days | After 14 days |
| Trichomoniasis | NAAT or rapid antigen | Swab or urine | 5 to 28 days | 2 to 4 weeks |
Rapid test, lab test, or clinic visit: how to choose
Picture two scenarios. In the first, you wait 20 minutes for a result you can read in your own kitchen, with no one else involved. In the second, you drive to a clinic, wait for the blood draw, and wait again for the lab to call. Both are real choices, and they answer different questions.
At-home rapid tests are built for privacy and speed. Sensitivity is solid once you are past the window period, which is why they work well as routine between-injection check-ins. They are less reliable in the first few weeks after a fresh exposure, when antibody levels are still rising.
Clinic visits add specificity and earlier detection. NAT testing in particular can flag infection while a rapid antibody kit would still read negative. Clinic visits also give you access to confirmatory testing, viral load measurement, and a conversation with someone who can read the result in the context of your full chart.
The right choice depends on what you need to know and when. The table below lays out the trade-offs.
| Option | Privacy | Speed | Sensitivity / Detection Window | Best Fit When |
|---|---|---|---|---|
| At-home rapid antibody test | Very high | Result in about 20 minutes | Reliable after roughly 90 days post-exposure | You want a private between-injection check-in |
| Clinic visit with lab Ag-Ab or NAT | Moderate | Same day to a few business days | Highest. Detects infection from 10 to 33 days (NAT) or 18 to 45 days (Ag-Ab) | You have a recent exposure, symptoms, or need viral load measurement |
| Confirmatory testing after a reactive home test | Moderate | Days, not minutes | Highest possible | Any reactive at-home result, especially on a long-acting regimen |
When to test after a possible exposure
A possible exposure puts the clock on the timeline. Whether the trigger was a condom break, shared injection equipment, or a partner who just disclosed a new diagnosis, the instinct to test immediately is understandable. It is also one of the most common mistakes.
If less than 72 hours have passed and you are at significant risk, post-exposure prophylaxis (PEP) is a clinical option that can prevent HIV from establishing infection. PEP must be started within 72 hours of exposure, and the sooner the better, with every hour counting (CDC PEP guidance). That is a clinic or urgent-care conversation, not a home-test one.
Between roughly 10 and 33 days after exposure, NAT testing can begin to detect the virus, though follow-up testing is usually still needed. Antigen and antibody combo tests become reliable around the 18 to 45 day mark in lab settings, per CDC testing guidance. At-home rapid antibody tests reach their peak accuracy after the 90-day window for most people, which is why retesting at the three-month point is a common recommendation when an initial result was negative.
Consider a typical scenario. A 62-year-old on a stable injectable regimen learns a recent partner has just tested positive. A rapid test five days later would almost certainly come back negative because antibody levels have not yet risen, not because nothing happened. The right move is to contact a provider about PEP if the exposure was within the past 72 hours, schedule a clinic visit for early NAT testing, and plan to retest at home or in clinic at the appropriate window.
Do you need to retest? How to know
Retesting after a previous negative or after a treatment change comes up often in midlife HIV care. The rules of thumb are simple, and each one has a reason behind it.
If your last test was negative and you have not had a new exposure since, routine retesting depends on your overall risk profile. The CDC suggests at least annual testing for sexually active adults at ongoing risk, with more frequent testing tied to specific risk factors.
If you are already living with HIV and on a long-acting injectable, a 30 to 45 day spacing for between-clinic at-home check-ins is a reasonable cadence, especially around a missed or delayed dose. Think of it as the equivalent of checking your blood pressure between cardiology visits: a way to flag something early, not a substitute for the formal viral load measurement your clinic runs.
Picture this. Someone in their late sixties forgets a scheduled 2-month injection while traveling and arrives home two weeks late. The rapid test they take at home reads reactive. A follow-up clinic NAT confirms a low-level rebound, the regimen restarts, and the person returns to suppressed status within weeks.
If you are not living with HIV: the CDC recommends at least annual testing for sexually active adults at ongoing risk, with more frequent testing tied to specific risk factors.
If you are on a long-acting injectable: aim for one at-home rapid check-in roughly halfway between scheduled shots, plus extra testing if you miss or delay a dose, develop symptoms, or have a possible new exposure. The home result does not replace your clinic's viral load measurement; it flags when to call ahead.
Privacy, shipping, and discretion
If you have ever worried about a delivery driver leaving a labeled medical box on your porch, you are not alone. Privacy is one of the most cited reasons people choose at-home testing over clinic visits, and it matters more, not less, as people age into living situations they did not anticipate (adult children at home, shared caregiving arrangements, retirement communities with thin walls).
Our kits ship in unmarked packaging. The shipping label does not name the product, the contents, or the testing condition. Tracking is available through standard carrier links, and most readers receive their kits within a few business days. For people coordinating their HIV care without disclosing their status to everyone in their household, that level of control is meaningful.
Discretion extends past the box. Results stay on the test cassette in your hand. No health record is created by an at-home rapid test that a provider, family member, or insurer can access without your sharing it. That is a different model from clinic testing, which has its own privacy protections but also creates a documented result.
- Unmarked outer packaging. The shipping label does not display the product name, the testing condition, or any branding that would identify the contents to a roommate, family member, or delivery driver.
- No automatic health record. An at-home rapid test does not create a documented result in your medical chart, your insurance file, or anywhere a provider or insurer can access without you sharing it.
- Results stay in your hand. The cassette is the only place the result is recorded. You decide whether and when to bring that information into a clinical conversation.
What if your at-home test is reactive
A reactive at-home result is unsettling, especially if you have been suppressed for years. Take a breath. A reactive home rapid does not mean your treatment has failed, and it does not mean you are infectious in that moment. It means it is time to call your provider for confirmatory testing (HIV.gov: Understanding HIV Test Results).
For someone newly testing, a reactive result needs a follow-up NAT or antigen and antibody combo at a clinic or lab to confirm. False positives on rapid antibody tests are uncommon but possible, which is why confirmatory testing is the universal next step. If confirmed, treatment with antiretroviral therapy should start as soon as possible. Most people reach an undetectable viral load within six months of beginning consistent therapy (CDC: HIV Treatment as Prevention).
For someone already on a long-acting injectable, a reactive home test points to two main possibilities. A delayed or missed injection has let viral replication restart, or, far less commonly, the current regimen is failing. In either case, the provider conversation is the priority, and the conversation usually leads to a clinic viral load measurement, possible resistance testing, and a plan to either resume injections or change therapy.
One scenario worth knowing. An older adult living alone misses a scheduled clinic visit because of weather, transportation, or a medical event of their own. They feel fine but use an at-home rapid as a precaution. The result is reactive. The clinic confirms a low-level rebound, restarts injections with a bridge plan, and the person stays on track.
The bottom line
The transition to long-acting injectable HIV therapy can lift a real weight off daily life. It does not eliminate the need for monitoring; it shifts where and when monitoring happens. Clinic visits set the foundation, and at-home rapid testing fills the gap in between when used the right way.
If you are weighing the switch, talk to your provider about whether the regimen fits your situation, your prior treatment history, and your hepatitis B status. If you are already on it, build at-home testing into your between-injection rhythm the same way you would a blood pressure check or a refill reminder. If you are newly diagnosed at midlife, you have more good options now than at any point in the four decades since HIV emerged as a public health concern.
A person with HIV who takes HIV medicine as prescribed and gets and stays virally suppressed or undetectable can stay healthy and will not transmit HIV to their sex partners.
Frequently Asked Questions
- Is injectable HIV therapy safe for people in their 60s and beyond?
- Real-world data from the 2025 RELATIVITY cohort (370 participants aged 60 and over) and a January 2026 study of 135 people aged 65 and over showed sustained viral suppression on bimonthly cabotegravir plus rilpivirine, with adherence rates that ran higher in the older group than in younger participants. Most adverse effects were tolerability issues like injection-site reactions or mild systemic symptoms. Your provider will still weigh your specific situation, including past resistance history and hepatitis B status, before recommending the switch.
- Do at-home rapid tests measure viral load?
- No. Most at-home rapid kits detect HIV antibodies, not viral RNA, so they cannot give you a viral load number. They can tell you whether antibodies are present, which is useful for screening and as a between-clinic check-in. If you have been suppressed for years and a rapid test reads reactive, treat it as a flag to schedule a clinic NAT (the lab test that actually counts viral copies), not as a definitive answer about your regimen.
- How often should I self-test between injections?
- Your clinic measures viral load every few months. An at-home rapid check fills the monitoring gap between those visits, so think of it as the home counterpart to lab work, not a replacement. The middle of the gap between scheduled shots is a natural trigger point. Add an extra check-in any time you miss or delay a dose, develop symptoms that worry you, or have a possible new exposure.
- What if my self-test reads reactive?
- Do not panic, and do not delay. A reactive at-home rapid test needs confirmatory lab testing, almost always a NAT or an antigen and antibody combo test at a clinic. Call your HIV provider or a local clinic, explain that you got a reactive home result, and ask about timing for the confirmatory test. Whether you are newly testing or already on an injectable regimen, the next move is the same: confirm in the lab.
- I missed an injection appointment. Now what?
- Contact your provider. The exact recovery plan depends on how late you are, your prior history, and your current suppression status. Late doses can let drug levels drop below the threshold that keeps the virus suppressed, which is why even a few weeks late warrants a phone call. An at-home rapid test while you wait for the appointment can give you a between-visit data point, though it is not a substitute for the clinic conversation.
- Are the injection side effects serious?
- The 2026 OFID study reported that the 11.1 percent who stopped the injectable did so for tolerability issues including injection-site reactions and systemic symptoms like myalgia or fever, or for personal preference. Serious adverse events were uncommon, though they did occur in rare cases (the same study documented one hepatitis B reactivation about 19 months in). For most people the day-after experience is mild and short-lived. Talk to your provider about what to expect with the first few doses.
- Am I still able to transmit HIV on long-acting therapy?
- If your viral load is undetectable, the risk of sexually transmitting HIV to a partner is effectively zero. That is the U=U principle (undetectable equals untransmittable), confirmed across multiple major studies. Long-acting cabotegravir plus rilpivirine is designed to keep you at undetectable as long as injections happen on schedule. Missed or significantly late doses can shift that picture, which is part of why between-injection check-ins matter.
- Is long-acting injectable HIV treatment covered by insurance or Medicare?
- Coverage is widespread but plan-specific. Most commercial plans and Medicare Part D cover cabotegravir plus rilpivirine when prescribed for an appropriate indication, often with prior authorization. Patient-assistance programs from the manufacturer can offset costs for people who qualify. Your clinic, a telehealth HIV service, or a state-level Ryan White program can help you sort out the paperwork. Do not assume out-of-pocket cost without asking first.
- Troya J. et al. Clinical outcomes of long-acting cabotegravir and rilpivirine in people with HIV aged 60 and older: real-world data from the Spanish RELATIVITY cohort. HIV Medicine, October 2025. The 370-participant analysis cited for the headline efficacy and adherence comparisons in older adults. Specific adherence percentages are drawn from the print edition.
- Bimonthly Administered Long-Acting Cabotegravir and Rilpivirine Are Highly Effective and Well-Tolerated in People With HIV Above 65 Years. Open Forum Infectious Diseases, January 2026. The 135-participant study covering people aged 65 and over, cited for the 17.4-month follow-up data, the 11.1 percent discontinuation rate, the breakdown of tolerability versus preference reasons, and the documented HBV reactivation case.
- U.S. Centers for Disease Control and Prevention. Getting Tested for HIV. The reference for window-period figures across NAT, antigen and antibody combo, and rapid antibody test types.
- U.S. Centers for Disease Control and Prevention. Preventing HIV with PEP. The reference for the 72-hour PEP initiation window and the 'sooner is better' framing for time-sensitive PEP eligibility.
- HIV.gov. Understanding HIV Test Results. The reference for guidance on confirmatory testing after a reactive home result and on what negative and positive results mean.
- U.S. Centers for Disease Control and Prevention. HIV Treatment as Prevention. The reference for the U=U principle (undetectable equals untransmittable) and for the six-month typical timeline to reach undetectable on consistent therapy. The quote in the article is taken verbatim from this page.
